MRTX849

covalent KRASG12C inhibitor

in clinical development for KRASG12C+ cancers

from optimization of known starting point

J. Med. Chem., Apr. 6, 2020

Array / Mirati Therapeutics

April 2020’s molecule, the Mirati KRAS G12C inhibitor MRTX849, has been a hotly followed compound in development as it is the closest clinical KRAS inhibitor to the likely soon-to-be approved…


 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.